10.6084/M9.FIGSHARE.11309645.V1
Amy S. Paller
Amy S.
Paller
Ashish Bansal
Ashish
Bansal
Eric L. Simpson
Eric
L. Simpson
Mark Boguniewicz
Mark
Boguniewicz
Andrew Blauvelt
Andrew
Blauvelt
Elaine C. Siegfried
Elaine C.
Siegfried
Emma Guttman-Yassky
Emma
Guttman-Yassky
Thomas Hultsch
Thomas
Hultsch
Zhen Chen
Zhen
Chen
Paola Mina-Osorio
Paola
Mina-Osorio
0000-0003-2986-9642
Yufang Lu
Yufang
Lu
Ana B. Rossi
Ana B.
Rossi
0000-0001-5345-678X
Xinyi He
Xinyi
He
Mohamed Kamal
Mohamed
Kamal
Neil M. H. Graham
Neil M. H.
Graham
Gianluca Pirozzi
Gianluca
Pirozzi
Marcella Ruddy
Marcella
Ruddy
Laurent Eckert
Laurent
Eckert
Abhijit Gadkari
Abhijit
Gadkari
Clinically meaningful responses with dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post hoc analyses from a randomized clinical trial
<p>This Figshare page contains a video abstract and summary slide.</p><p><strong><br></strong></p><p></p><p><b>Disclosures</b></p>
<p><b>Funding</b></p>
<p>Open access was funded by Sanofi and Regeneron
Pharmaceuticals, Inc. The current research was sponsored by Sanofi and
Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT03054428. The
study sponsors participated in the study design; collection, analysis, and
interpretation of the data; writing of the report; and the decision to submit
the article for publication. Medical writing/editorial assistance was provided
by Carolyn Ellenberger, PhD, of Excerpta Medica, funded by Sanofi Genzyme and
Regeneron Pharmaceuticals, Inc.</p>
<p><b> </b></p>
<p><b>Potential
Conflicts of Interest</b></p>
<p>Amy
S. Paller has served as an investigator and/or consultant for AbbVie, Amgen,
AnaptysBio, Asana, Dermavant, Dermira, Eli Lilly, Galderma, Forte, Incyte,
Janssen, LEO Pharma, Matrisys Bioscience, Menlo Therapeutics,
MorphoSys/Galapagos, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and
Sanofi. Ashish Bansal, Zhen Chen, Paola Mina-Osorio, Yufang Lu, Xinyi He,
Mohamed Kamal, Neil M. H. Graham, Marcella Ruddy, and Abhijit Gadkari are
employees and shareholders of Regeneron Pharmaceuticals, Inc. Eric L. Simpson
served as an investigator and/or consultant for AbbVie, Boehringer Ingelheim,
Dermavant, Eli Lilly, Galderma, Forte, Incyte, Kyowa Hakko Kirin, LEO Pharma,
Merck, Menlo Therapeutics, Pfizer, Pierre Fabre Dermo Cosmetique, Regeneron
Pharmaceuticals, Inc., Sanofi Genzyme, and Valeant. Mark Boguniewicz served as
an investigator and/or consultant for Regeneron Pharmaceuticals, Inc. and
Sanofi Genzyme. Andrew Blauvelt served as a consultant and investigator for
AbbVie, Aclaris, Akros, Allergan, Almirall, Amgen, Arena, Boehringer Ingelheim,
Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Galderma,
Genentech/Roche, GlaxoSmithKline, Janssen, LEO Pharma, Meiji, Merck Sharp &
Dohme, Novartis, Pfizer, Purdue Pharma, Regeneron Pharmaceuticals, Inc.,
Revance, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB
Pharma, Valeant, and Vidac and served as a speaker for Janssen, Regeneron
Pharmaceuticals, Inc., and Sanofi Genzyme. Elaine C. Siegfried served as a
principal investigator for AbbVie, Boehringer Ingelheim, Celgene, Dermavant,
Dermira, Eli Lilly, LEO Pharma, Novan, Novartis, Pfizer, Regeneron
Pharmaceuticals, Inc., Sanofi, and UCB and as an investigator for Allergan, Eli
Lilly, Janssen, Mayne, Regeneron Pharmaceuticals, Inc., and Verrica. Emma
Guttman-Yassky served as an investigator for AbbVie, Celgene, Eli Lilly,
Galderma, GlaxoSmithKline, Glenmark, LEO Pharma, Pfizer, Regeneron
Pharmaceuticals, Inc., and Sanofi; as a consultant for AbbVie, Anacor, Asana
Biosciences, Daiichi Sankyo, DBV Technologies, Dermira, Eli Lilly, Galderma,
GlaxoSmithKline, Glenmark, Kiniksa, Kyowa, LEO Pharma, Menlo Therapeutics,
Novartis, Pfizer, Realm, Regeneron Pharmaceuticals, Inc., and Sanofi and
received research support from AbbVie, Celgene, Dermira, Galderma, Innovaderm,
Janssen, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and
Sanofi. Thomas Hultsch, Ana B. Rossi, Gianluca Pirozzi, and Laurent Eckert are
employees of Sanofi, and own Sanofi stock/stock options.</p>
<p><b>Ethics
approval</b></p>
<p>LIBERTY
AD ADOL was conducted in accordance with the ethical standards of the
responsible committees and the Declaration of Helsinki and with the
International Conference on Harmonization guidelines for Good Clinical
Practice. The trial was overseen by an independent data and safety monitoring
board.</p>
<p><b>Consent
to participate</b><br></p>
<p>Written
informed consent was obtained from all patients or their proxies.</p><p><br></p>
<p>©
The Author(s) 2019</p><br><p></p>
Medicine
Dermatology
Adis Journals
2019
2019-12-11
2024-02-16
Media
215382669 Bytes
10.6084/m9.figshare.11309645
https://link.springer.com/article/10.1007/s40257-019-00478-y
10.1007/s40257-019-00478-y
CC BY-NC 4.0